Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient

Aitomi Bittnera Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyCorrespondence[email protected]

https://orcid.org/0000-0001-6434-0950

Josefine Radkeb Berlin Institute of Health (BIH), Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;d Department of Neuropathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Dennis Euriche Department of Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Edzard Wienerf Institute of Neuroradiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Sophy Denkera Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Ioannis Anagnostopoulosg Institute of Pathology, University of Würzburg, Würzburg, Germany

Il-Kang Naa Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;b Berlin Institute of Health (BIH), Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;h Experimental and Clinical Research Center (ECRC), Berlin, Germany;i BIH Centre for Regenerative Therapies, Berlin, Germany

Frank L. Heppnerb Berlin Institute of Health (BIH), Berlin, Germany;d Department of Neuropathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;j Cluster of Excellence, NeuroCure, Berlin, Germany;k German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

Lars Bullingera Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;b Berlin Institute of Health (BIH), Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;l Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Clemens A. Schmitta Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;l Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany;m Department of Hematology and Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria

show all

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date